SCORE

SWIFT CORONAVIRUS THERAPEUTICS RESPONSE

Introducing the SCORE consortium

The SCORE consortium represents a team of eight European universities, institutes and pharmaceutical companies aimed at the development of SARS-CoV-2 antiviral drugs. This multidisciplinary consortium has already a long-established collaboration on coronavirus research. Since April 2020 an EU-funding program in response to the Covid-19 pandemic has allowed us to a accelerate our antiviral drug development program.



The consortium activities are placed in work packages

1 - Phenotypic screening for selective inhibitors
2 - Nucleoside/tide inhibitors
3 - Inhibitors of coronavirus proteases
4 - Identification of drugs targeting 2019-nCoV entry
5 - The nCoV toolbox
6 - Animal Models

During the first six months the consortium has created a toolbox of SARS-CoV-2 virus isolates, reagents, assays and standard operating procedures. In the first work package, screening of our available libraries have already resulted in five new compound lines which inhibit the virus in inhibition assays, and which are currently being further characterized and chemically optimized. Large scale screening of repurposed drug libraries did not result in any significant SARS-CoV-2 inhibitors, which confirm results from other international efforts.



High-throughput SARS-CoV-2 Inhibition Screenings Assays

All our results are published in order to maximize the impact of our results. During the first six months our partners have already published 12 open access scientific publications including:

- **Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors** DOI: 10.1126/science.abb3405
- **Rapid reconstruction of SARS-CoV-2 using a synthetic genomics platform.** DOI: 10.1038/s41586-020-2294-9
- **A molecular pore spans the double membrane of the coronavirus replication organelle** DOI: 10.1126/science.abd3629
- **A Fluorescence-based High Throughput-Screening assay for the SARS-CoV-2 RNA synthesis complex** DOI: 10.1101/2020.07.07.192005
- **Drugs against SARS-CoV-2: What do we know about their mode of action?** DOI: 10.1002/rmv.2143

The SCORE project has received funding from the European Union's Horizon 2020 research and innovation program under grant agreement No 101003627.

Contact
W: www.score.cov.eu
T: +31 6 17754637
E: e.d.l.schmidt@lumc.nl